Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2007

View Archived Issues

Novel animation depicting GLP-1 and DPP IV as therapeutic targets for diabetes and obesity

STRIDE preliminary results reveal safety and activity of I-vation Triamcinolone Intravitreal Implant

Common pathogenic mechanisms in AD and ocular degenerative diseases

Recent patents disclose new anxiolytic and antipsychotic agents

Therapeutic agents for allergic and respiratory disorders described in recent patents

Promising neuroprotective and antioxidant effects of AEOL-11207 in an MPTP model of Parkinsonism

Recent patents impart novel treatment options for autoimmune and inflammatory disorders

Accentia reaches milestone in SinuNase development; CRSFungal Profile commercialized

Commercialization agreement signed for NeuroBloc

ODAC to review satraplatin in July

Paramount BioSciences obtains license to SonoLight technology for dermatology indications

Boehringer Ingelheim announces measure to expand reach of HIV therapy

Patient enrollment begins in Aridol trial for COPD

Interim analysis of talabostat phase III NSCLC clinical trial to be conducted

SIGA's Lassa fever drug candidate shows promise in animal models

Indaflex shows potential in phase II for osteoarthritis

Testosterone improves cognitive performance in multiple sclerosis

Promising phase IIa study results reported for house dust mite allergy product candidate

Oxycyte reaches primary endpoint in TBI phase IIa trial

Luitpold seeks FDA approval for iron replacement therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...